Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The optimal duration of systemic treatment in patients with advanced colorectal cancer is
unknown.
In this study the effects of bevacizumab and low-dose continuous chemotherapy with
capecitabine is investigated in patients who have responded to 6 courses of oxaliplatin,
capecitabine and bevacizumab ("induction treatment", at standard doses). This treatment is
continued until progression or severe toxicity. This regimen is compared to the effects a
observation without treatment after the induction treatment.
In case of disease progression, induction treatment will be reintroduced.